The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.
Our lead product, pidilizumab (CT-011), is a humanized monoclonal antibody that interacts with PD-1, a B7 receptor-family-associated protein, and exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumors. A Phase II program has been initiated including 3 sponsored studies: the first, a Phase II clinical trial in patients with diffuse large B cell lymphoma has been completed. Enrolment to 2 additional Phase II studies in patients with metastatic colorectal cancer and metastatic melanoma has been completed. In addition to these 3 studies, several investigator-initiated studies in different indications including follicular lymphoma, multiple myeloma, AML, renal cell carcinoma, pancreatic cancer and prostate cancer are ongoing.